Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer-Reference-Cited by-同舟云学术

Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer

Published:2014-04 Issue:1 Volume:84 Page:62-66
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Heigener D.F.,Deppermann K.M.,Pawel J.v.,Fischer J.R.,Kortsik C.,Bohnet S.,Eiff M.v.,Koester W.,Thomas M.,Schnabel P.A.,Reck M.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference12 articles.

1. Gesundheitsberichterstattung des Bundes;Gesundheit in Deutschland,2006

2. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer;Davidoff;J Clin Oncol,2010

3. The ELVIS trial: a phase III study of single-agent Vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study;Gridelli;Oncologist,2001

4. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

5. Second-line Erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study;Heigener;Lung Cancer,2011

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF);Cancers;2022-02-02

2. Drug-induced diarrhea associated with antineoplastic drugs;HERALD of North-Western State Medical University named after I.I. Mechnikov;2021-10-15

3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer;Cochrane Database of Systematic Reviews;2021-03-18

4. Pharmacogenetics of advanced lung cancer: Predictive value of functional genetic polymorphism AGXT Pro11Leu in clinical outcome?;Pulmonology;2021-03

5. Targeted Therapies;Encyclopedia of Gerontology and Population Aging;2021